Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 6,517 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Cavity Clear all
Completed Not applicable Interventional

LEAVE Safe With DOACs

NCT04068727
View directory record Official record
Conditions
Cardiovascular Diseases, Venous Thromboembolism, Atrial Fibrillation, Bleeding, Stroke
Interventions
Clinical Pharmacist Intervention
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 28, 2026, 5:09 AM EDT
Withdrawn Not applicable Interventional

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

NCT03046901
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions
Vancomycin
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 28, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reducing Risk for Infective Endocarditis

NCT05721781
View directory record Official record
Conditions
Bacteremia, Infective Endocarditis
Interventions
Oral Hygiene instruction, Dental Cleaning
Behavioral · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Newark, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 5:09 AM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

NCT01552772
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

NCT02229539
View directory record Official record
Conditions
Acute Oral Mucositis Pain
Interventions
doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
350
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 221 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of AG120 in Healthy Subjects

NCT02831972
View directory record Official record
Conditions
Healthy
Interventions
AG120, Itraconazole
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 28, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

NCT07610395
View directory record Official record
Conditions
Rhinovirus Infection
Interventions
VPV 1000 mg, VPV 500 mg, Placebo
Drug · Other
Lead sponsor
Altesa Biosciences, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
37
States / cities
Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

NCT06344728
View directory record Official record
Conditions
Healthy Participants
Interventions
Brensocatib Oral Solution, Brensocatib Oral Tablet
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00337129
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
eribulin mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
139
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 90 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 28, 2026, 5:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

NCT06077877
View directory record Official record
Conditions
Neoplasms
Interventions
GSK4524101, Niraparib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
San Francisco, California • St Louis, Missouri • Dallas, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT00949130
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
NXL103, Linezolid
Drug
Lead sponsor
Novexel Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Chula Vista, California • Fountain Valley, California • La Mesa, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

NCT00357500
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
celecoxib, cyclophosphamide, etoposide, fenofibrate, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

NCT04777409
View directory record Official record
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

NCT00002112
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Study of Oral Morphine Sulfate Administration in Pediatric Subjects

NCT03429400
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Morphine Sulfate
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
2 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sheffield, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents

NCT01134536
View directory record Official record
Conditions
Pain, Postoperative, Postoperative Pain
Interventions
Tapentadol (OS) Oral Solution
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

NCT05064332
View directory record Official record
Conditions
Healthy
Interventions
PF-06650833, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers

NCT01023100
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP 690,550 oral solutions
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2010 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

NCT06275464
View directory record Official record
Conditions
Healthy
Interventions
BT-600, BT-600 Placebo
Combination Product
Lead sponsor
Biora Therapeutics, Inc.
Industry
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity

NCT02476032
View directory record Official record
Conditions
Tooth Sensitivity
Interventions
Prof applied oxalate, Self applied oxalate, Prof applied placebo
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function

NCT00002901
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 28, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

NCT01744730
View directory record Official record
Conditions
Bacterial Infections, Obesity
Interventions
Clindamycin
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 28, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

NCT06044311
View directory record Official record
Conditions
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
Interventions
Vactosertib, Standard of Care Preoperative Therapy
Drug
Lead sponsor
Melissa Lumish
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 5:09 AM EDT